Suppr超能文献

塞来昔布诱导的肺ALK阴性浆细胞性肉芽肿(炎性肌纤维母细胞瘤)完全缓解:一例报告并文献复习

Complete remission of ALK-negative plasma cell granuloma (inflammatory myofibroblastic tumor) of the lung induced by celecoxib: A case report and review of the literature.

作者信息

Chavez Cinderella, Hoffman Mark A

机构信息

Division of Hematology-Oncology, Department of Medicine, Long-Island Jewish Medical Center, North Shore-LIJ Health System, New Hyde Park, NY 11040, USA.

出版信息

Oncol Lett. 2013 May;5(5):1672-1676. doi: 10.3892/ol.2013.1260. Epub 2013 Mar 15.

Abstract

We report a case in which a 52-year-old female developed a multifocal inflammatory myofibroblastic tumor (IMT) of the lung. The tumor did not overexpress the anaplastic lymphoma kinase (ALK) protein, indicating a lack of ALK rearrangement. The patient required two wedge resections in 15 months due to recurrent disease. Recurrence after the second surgery was treated with corticosteroids, which only led to a transient response (6 months). Introduction of celecoxib, a cyclooxygenase-2 inhibitor, induced a complete remission in the patient. Maintenance on celecoxib further led to a progression-free survival of 34 months. A literature review retrieved a total of eight case reports, comprising ten patients, of IMT of various anatomical sites successfully treated with non-steroidal anti-inflammatory agent (NSAID) therapy. Nine of the ten patients achieved durable complete remission. Remission occurred rapidly and persisted even after termination of NSAID therapy. Although such a successful outcome may only be achieved rarely, a trial of an NSAID should be considered in any patient in whom complete resection is not an option. Our case also demonstrates that NSAID therapy may be successful in a non-ALK rearranged tumor in which ALK inhibition is not an option.

摘要

我们报告了一例52岁女性发生肺部多灶性炎性肌纤维母细胞瘤(IMT)的病例。该肿瘤未过度表达间变性淋巴瘤激酶(ALK)蛋白,提示不存在ALK重排。由于疾病复发,患者在15个月内接受了两次楔形切除术。第二次手术后的复发采用皮质类固醇治疗,仅产生了短暂反应(6个月)。引入环氧化酶-2抑制剂塞来昔布后,患者实现了完全缓解。持续使用塞来昔布进一步导致了34个月的无进展生存期。文献综述共检索到8例病例报告,包括10名患者,这些患者的不同解剖部位的IMT采用非甾体抗炎药(NSAID)治疗成功。10名患者中有9名实现了持久的完全缓解。缓解迅速出现,即使在NSAID治疗终止后仍持续存在。尽管这种成功的结果可能很少见,但对于任何无法进行完全切除的患者,都应考虑试用NSAID。我们的病例还表明,NSAID治疗对于无法选择ALK抑制治疗的非ALK重排肿瘤可能是成功的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5e2/3678867/3b701d256c73/OL-05-05-1672-g00.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验